Mimetic Peptides Stabilize L-Type Calcium Channels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with altered L-type calcium channel (LTCC) density and function are inadequate, leading to adverse effects and a need for more target-specific therapeutic approaches to modulate intracellular Ca2+ handling in excitable cells.
Innovation Solution
Development of novel mimetic peptides that bind to the Tail Interacting Domain (TID) of the Ca v β2 protein, specifically extending the half-life of the Ca v α1.2 protein and modulating LTCC density and function, thereby restoring intracellular Ca2+ handling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for conditions with altered LTCC density, then intracellular Ca2+ handling is modulated, but adverse effects occur and target specificity is insufficient
Solution Approach 1:
The patent uses peptide mimetics as intermediary molecules that specifically bind to the TID domain of CaVβ2 protein. These peptides act as mediators between the therapeutic goal (modulating LTCC density) and the target protein, providing selective interaction that avoids off-target effects of conventional drugs. The peptides serve as a precise intermediary mechanism to restore intracellular Ca2+ handling without the adverse effects of non-specific current treatments.
2Adaptability or versatility
If conventional drugs are used to treat altered LTCC conditions, then broad therapeutic action is achieved, but target specificity is reduced
Solution Approach 1:
The patent applies local quality by designing peptides with specific amino acid sequences that target only the TID domain of CaVβ2 protein. The peptides contain localized functional regions (such as the core sequence DQRPDREAP) that bind specifically to the TID binding site, providing highly localized and specific interaction. This local specificity allows the therapy to act precisely on LTCCs without affecting other calcium channels or proteins, achieving both therapeutic action and target precision.
3Stability of the object's composition
If LTCC density is altered in disease states, then intracellular Ca2+ homeostasis is disrupted, but current treatments cannot effectively restore it
Solution Approach 1:
The patent employs preliminary action by using peptide mimetics that prevent the degradation of CaVα1.2 protein through binding to the TID domain of CaVβ2. The peptides act in advance to stabilize the channel protein and prevent its turnover, thereby maintaining LTCC density before complete disruption of Ca2+ homeostasis occurs. This preliminary stabilization mechanism effectively restores and maintains intracellular Ca2+ homeostasis in disease states where LTCC density is altered.
Data Source
Figure 1
Figure 2a~2c
Figure 3a~3d
AI summary
The present invention concerns the field of ion channels, and in particular relates to peptides which are suitable for use in the treatment of conditions where the L-type calcium channel (LTCC) density and function is altered. LTCCs are located on the membrane of all excitable cells and control the small voltage gradient across the plasma membrane by allowing the flow of Ca2+ ions down their electrochemical gradient. This Ca2+ flux is critical for numerous processes including cardiac action potential propagation, muscle contraction, Ca2+ -dependent gene expression, synaptic efficacy, and cell survival by contributing to various signaling cascades. Reduction of the inward calcium current (I Ca) conducted through the LTCCs is seen in several diseases and medications to improve or restores impaired intracellular Ca2+ homeostasis are limited. The present invention reports mimetic peptides (MPs) that through a novel mechanism directly targets LTCCs and, by modulation of LTCC density and function, increases ICa. This invention supports a therapeutic role for MP to treat human diseases associated with altered cellular Ca2+ homeostasis.